probenecid has been researched along with Renal Insufficiency in 8 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In conclusion, this first established pharmacokinetic model provides a tool to achieve target oxypurinol plasma concentrations, thereby optimizing the effectiveness and safety of allopurinol therapy in gouty patients with various degrees of renal impairment." | 7.78 | The pharmacokinetics of oxypurinol in people with gout. ( Day, RO; Graham, GG; Kirkpatrick, CM; McLachlan, AJ; Savic, RM; Stocker, SL; Williams, KM, 2012) |
| "In conclusion, this first established pharmacokinetic model provides a tool to achieve target oxypurinol plasma concentrations, thereby optimizing the effectiveness and safety of allopurinol therapy in gouty patients with various degrees of renal impairment." | 3.78 | The pharmacokinetics of oxypurinol in people with gout. ( Day, RO; Graham, GG; Kirkpatrick, CM; McLachlan, AJ; Savic, RM; Stocker, SL; Williams, KM, 2012) |
| "In a cohort of veterans with a diagnosis of gout prescribed allopurinol, colchicine or probenecid, quality of care was assessed by examining adherence to the following evidence-based recommendations: (1) whether patients starting a new allopurinol prescription (a) received continuous allopurinol, (b) received colchicine prophylaxis, (c) achieved the target uric acid level of | 3.75 | Opportunities for improving medication use and monitoring in gout. ( Asch, SM; Hodges, JS; Singh, JA, 2009) |
| " Intracellular activation of a small fraction (< 10%) of the dose by cellular kinases leads to prolonged antiviral effects that are not easily predicted from conventional pharmacokinetic studies." | 2.40 | Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. ( Cundy, KC, 1999) |
| "Repeat labs also showed new onset renal failure." | 1.43 | Penicillin Encephalopathy: An Unlikely Adversary in the Treatment of Neurosyphilis--Case Report and Review of the Literature. ( Covelli, V; Khanapara, DB; Naut, ER, 2016) |
| "Morinidazole is a novel 5-nitroimidazole antimicrobial drug that undergoes extensive metabolism in humans via N(+)-glucuronidation (N(+)-glucuronide of S-morinidazole [M8-1] and N(+)-glucuronide of R-morinidazole [M8-2]) and sulfation (sulfate conjugate of morinidazole [M7])." | 1.40 | Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites. ( Chen, X; Li, X; Xie, C; Zhang, Y; Zhong, D; Zhong, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, K | 1 |
| Li, X | 1 |
| Xie, C | 1 |
| Zhang, Y | 1 |
| Zhong, D | 1 |
| Chen, X | 1 |
| Covelli, V | 1 |
| Khanapara, DB | 1 |
| Naut, ER | 1 |
| Singh, JA | 1 |
| Hodges, JS | 1 |
| Asch, SM | 1 |
| Stocker, SL | 1 |
| McLachlan, AJ | 1 |
| Savic, RM | 1 |
| Kirkpatrick, CM | 1 |
| Graham, GG | 1 |
| Williams, KM | 1 |
| Day, RO | 1 |
| PHILLIPS, RW | 1 |
| HAAGENSEN, NR | 1 |
| NIELSEN, B | 1 |
| D ANGLEJEAN, G | 1 |
| Cundy, KC | 1 |
1 review available for probenecid and Renal Insufficiency
| Article | Year |
|---|---|
Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytosine; Drug Interactions; Hu | 1999 |
7 other studies available for probenecid and Renal Insufficiency
| Article | Year |
|---|---|
Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Cell Line; Cimetidine; Female; HEK293 Cells; Humans; | 2014 |
Penicillin Encephalopathy: An Unlikely Adversary in the Treatment of Neurosyphilis--Case Report and Review of the Literature.
Topics: Adjuvants, Pharmaceutic; Aged; Anti-Bacterial Agents; Brain Diseases; Female; HIV Infections; Humans | 2016 |
Opportunities for improving medication use and monitoring in gout.
Topics: Aged; Allopurinol; Biomarkers; Colchicine; Drug Administration Schedule; Drug Monitoring; Female; Go | 2009 |
The pharmacokinetics of oxypurinol in people with gout.
Topics: Adult; Aged; Aged, 80 and over; Diuretics; Drug Interactions; Enzyme Inhibitors; Female; Gout; Gout | 2012 |
Reversal of renal insufficiency in gout; report of a case treated with probenecid (benemid).
Topics: Gout; Humans; Kidney Diseases; Probenecid; Renal Insufficiency | 1955 |
The effect of probenecid on renal excretion and plasma level of uric acid in patients with renal insufficiency.
Topics: Humans; Kidney; Kidney Diseases; Metabolic Diseases; Probenecid; Renal Elimination; Renal Insufficie | 1961 |
[ASSESSMENT OF 172 CASES OF CHRONIC GOUT TREATED BY PROBENECID FOR 10 YEARS].
Topics: Acute Kidney Injury; Arthritis, Gouty; Gout; Humans; Kidney Calculi; Probenecid; Renal Insufficiency | 1963 |